Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
Neuroprotective Effect of Topical Administration of Brimonidine Purite in Rats with Laser-induced Chronic Ocular Hypertension
Banaskiewicz R.1, Vorwerk C. K.1, Ruiz G.2, Wheeler L. A.2, Wolde Mussie E.2
1Department of Ophthalmologie, Otto-von-Guericke-University Magdeburg; 2Department of Biological Sciences, Allergan Inc., Irvine, CA
Purpose: One of the main characteristics in glaucoma is the progressive lost of retinal Ganglion cells (RGC). Therefore is the development of protective drugs for the RGCs an important part in glaucoma research. The aim of this study was to examine the protective effect of topical administration of Brimonidine purite (Alphagan-P) in wistar-rats with laser-induced chronic ocular hypertension.
Method: Intraocular pressure (IOP) was elevated by laser photocoagulation of limbal and episcleral veins. Drug administration was begun on day 10-post laser treatment and continued for 21 days. Drug was applied twice a day in the laser treated eyes only. IOP was monitored weekly before and one hour after drug administration. The RGCs were labelled by retrograde transport with Dextran- Tetra- Methyl- Rhodamine and counted in whole mounted retinas.
Results: Laser treatment caused a two- fold increase in IOP. The treatment with Brimonidine caused a clearly decrease in IOP. The RGC lost 10 days after IOP elevation was 17%. At the end of the experiment in the vehicle treated groups was a 41% decrease in RGCs. In Brimonidin